Noxilizer Announces David A. Theil, Senior Vice President And CFO

Experienced Life Science Financial Executive Joins Management Team

January 26, 2016 (Baltimore, MD) Noxilizer, Inc., the company advancing a room temperature, NO2-based sterilization and decontamination process for bio-pharmaceutical and medical device manufacturers announces David A. Theil as their new Senior Vice President and Chief Financial Officer (CFO).

Mr. Theil specializes in private equity funded start-up and middle market companies in the Life Sciences industry and brings 25+ years of financial, administrative and operational management experience. Most recently, he worked as interim and contract CFO in the medical device and clinical diagnostics arenas. Previous industry employment appointments include: Supernus Pharmaceuticals, Specialty Pharmaceuticals; Psychiatric Genomics, Biotechnology R&D Drug Discovery; and IGEN International, Instrumentation and Diagnostics.

"David brings experience that is critical to Noxilizer at this stage of the company," states Lawrence Bruder, President & CEO. "He has worked in growing companies and understands the opportunities and challenges."

Mr. Theil also worked at Deloitte & Touche, as a Manager of Emerging Business Markets Group, where he served clients in biotechnology, communications, healthcare and other middle market technology companies. Mr. Theil obtained his BSc in Accounting from the Kelley School of Business at Indiana University, Bloomington IN, and holds a Delaware CPA certificate.

About Noxilizer, Inc.:

Noxilizer, Inc. provides room temperature nitrogen dioxide sterilization technology that offers many benefits over traditional sterilization methods. Noxilizer sells sterilization and biodecontamination equipment to pharmaceutical, biotech and medical device manufacturers and also offers contract sterilization services at its Baltimore, MD facilities. Noxilizer's expert microbiology and material compatibility team is ready to partner to solve sterilization challenges through every phase of the process. Noxilizer, Inc. is privately held with offices in the US, United Kingdom and Japan. For more information, please visit: www.noxilizer.com.

Suggested Articles

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.

While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera

The growth fund, which received money from Eil Lilly, will work with a who’s who of European biotech leaders to execute its investment strategy.